S

Sanofi

Global pharma company; vaccines and R&D

Production Technician

Full-TimeUpdated Deadline 11/4/26
$20.32 - $27.09
Entry
Bachelor's
Swiftwater, PA, USA
In PersonOnsite; shift assignment may be 1st, 2nd, or 3rd shift, with weekends and holidays as scheduled.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • High school diploma and 0–6 months of experience.
  • Good mechanical skills, computer skills, and attention to detail.
  • Basic mechanical aptitude, computer skills, comprehension and retention skills, troubleshooting ability, and manual dexterity.
  • Proficiency in at least one area of operation or product line.
  • Ability to lift up to 50 pounds.
  • Ability to stand an average of eight hours per shift.
  • Ability to gown and gain entry to manufacturing areas.
  • Ability to work a twelve-hour rotating shift and every other weekend, including holidays as scheduled.
  • Ability to flex into another platform within MTech or another Manufacturing & Supply department and to work weekends, holidays, or off-shift hours as needed.
  • For influenza production roles excluding FFIP roles, ability to receive the influenza vaccine required for building access.
  • For aseptic area production roles excluding Flu production technician roles, ability to obtain and maintain current aseptic gowning qualification.
  • Ability to work in multiple buildings and, as business needs require, to be temporarily moved or flexed to another department or building within the FFIP operation.
  • Ability to lift up to 25 pounds and bend, lift, and move objects.
  • Ability to stand for up to eight hours a day with occasional breaks.
Responsibilities
  • Operate in a cGMP manufacturing area, performing equipment setup and operations tasks in accordance with safety, quality, and efficiency standards.
  • Perform production in accordance with volume fluctuations, business needs, and effective procedures.
  • Ensure processes comply with FDA regulations.
  • Complete assigned training modules.
  • Identify and prevent deviations and assist with investigations and root cause analysis.
  • Assist with deviation investigations, Corrective and Preventive Actions, Change Control Requests, and other assigned projects.
  • Complete quality documents, including Batch Production Records and logbooks, accurately and on time, and ensure documentation is completed accurately in real time.
  • Prepare areas for the next shift to maintain smooth operations and efficiency.
  • Use materials responsibly and efficiently to reduce waste.
  • Share improvement ideas, issues, and concerns with team members and provide solutions.
  • Identify and solve production issues proactively to ensure smooth operations.
  • Model and uphold HSEEn standards and comply with safety procedures.
  • Promptly report safety concerns, near misses, equipment issues, and environmental incidents.
  • Participate in safety meetings, walkthroughs, and improvement initiatives.
  • Maintain a clean, organized, and safe work environment and perform necessary checks and inspections.
  • Support continuous improvement by providing input on corrective and preventive actions.
  • Perform other duties as assigned.
Desired Qualifications
  • Six months of experience in a cGMP environment or pharmaceutical experience.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...